Ambrisentan

證據等級: L5

預測適應症: 10 個

Ambrisentan: From Pulmonary Arterial Hypertension to Pulmonary Arteriovenous Malformation

One-Sentence Summary

Ambrisentan is a selective endothelin type A (ETA) receptor antagonist, approved internationally for pulmonary arterial hypertension (PAH) but not yet registered in India. The TxGNN model predicts it may be effective for Pulmonary Arteriovenous Malformation (AVM), with 0 clinical trials and 1 publication currently supporting this specific direction. Notably, co-predictions for PAH subtypes — including PAH associated with congenital heart disease (L2), HIV infection (L1), and connective tissue disease (L2) — carry substantially stronger evidence and represent more immediately actionable repurposing opportunities.

Quick Overview

Item	Content
Original Indication	Pulmonary Arterial Hypertension (PAH) — approved globally (US/EU); not registered in India
Predicted New Indication	Pulmonary Arteriovenous Malformation (disease)
TxGNN Prediction Score	99.41%
Evidence Level	L4
India Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Formal mechanism of action (MOA) data is not documented in this Evidence Pack. Based on established pharmacology, Ambrisentan is a highly selective endothelin type A (ETA) receptor antagonist. It competitively blocks ET-1 binding to ETA receptors on pulmonary arterial smooth muscle and endothelial cells, reducing pulmonary vasoconstriction and vascular remodeling — the core pathophysiology of PAH. Its selectivity for ETA over ETB is clinically relevant because preserved ETB receptor activity maintains endogenous NO production and vascular clearance of ET-1.

Pulmonary arteriovenous malformations (PAVMs) are predominantly structural vascular anomalies, most commonly arising in patients with Hereditary Hemorrhagic Telangiectasia (HHT), a rare autosomal dominant disorder caused by mutations in the ACVRL1 or ENG genes — both encoding components of the TGF-β/BMP signaling pathway. A subset of HHT patients (estimated 5–15%) concurrently develop PAH. It is in this specific HHT-PAH overlap population that an endothelin receptor antagonist like Ambrisentan could theoretically provide benefit. The mechanistic link is therefore indirect: Ambrisentan would target the PAH complication co-occurring with HHT, not the PAVM structural lesion itself.

The sole supporting publication (PMID 33969094) precisely describes this overlap scenario — an HHT patient who developed PAH and underwent PAH-targeted therapy, with family gene analysis revealing ACVRL1/ENG mutation implicating the endothelin signaling axis. The TxGNN model likely captured this biological connection through shared knowledge-graph nodes (ACVRL1/ENG ↔ endothelin pathway ↔ PAH), but this does not imply Ambrisentan can structurally reverse or ablate PAVM lesions. The prediction reflects a comorbidity-driven opportunity rather than a primary PAVM mechanism.

Clinical Trial Evidence

Currently no related clinical trials registered for Pulmonary Arteriovenous Malformation.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
33969094	2021	Case Report	World Journal of Clinical Cases	HHT patient with concurrent PAH treated with PAH-targeted therapy; family gene analysis identified ACVRL1/ENG mutation, illustrating the HHT-PAH co-morbidity where endothelin-axis therapies may be relevant

Safety Considerations

Drug Interactions: Ambrisentan has 112 documented interactions. The most clinically significant are listed below:

Interacting Drug	Severity	Clinical Note
Canagliflozin	Moderate	Monitor when co-administered
Dapagliflozin	Moderate	Monitor when co-administered
Empagliflozin	Moderate	Monitor when co-administered
Ertugliflozin	Moderate	Monitor when co-administered
Eliglustat	Moderate	Monitor when co-administered
Naltrexone	Moderate	Monitor when co-administered
Clarithromycin	Minor	Routine monitoring sufficient
Miconazole	Minor	Routine monitoring sufficient
Omeprazole	Minor	Routine monitoring sufficient

Please refer to the package insert for complete warnings and contraindications (formal India package insert data not available in this Evidence Pack).

Conclusion and Next Steps

Decision: Hold

Rationale: Although TxGNN assigns Pulmonary AVM the highest prediction score (99.41%), the mechanistic link is indirect — Ambrisentan targets PAH co-occurring in HHT patients rather than the AVM lesion itself — and clinical evidence is limited to a single case report, placing it at L4. This is insufficient to support clinical advancement for this specific indication. The more compelling repurposing story lies in the co-predicted PAH subtypes (ranks 2–4), all of which share the same ETA-antagonism mechanism and are supported by Phase 2/3 level evidence.

To proceed, the following is needed:

MOA documentation: Obtain formal DrugBank MOA and DrugBank categories to complete the mechanism-of-action analysis and confirm non-antineoplastic classification
Package insert review: Retrieve India or international package insert (Letairis/Volibris) for warnings, contraindications, and hepatotoxicity monitoring requirements
Redirect primary evaluation: Prioritize higher-evidence co-predictions:
- PAH-CHD (L2): NCT01808313, Phase 3b, completed in Chinese population — directly actionable for India market
- PAH-HIV (L1): NCT00709956, Phase 3 double-blind RCT — meets highest evidence threshold
- PAH-CTD (L2): Multiple completed trials including AMBITION post-hoc CTD-PAH subgroup (PMID 28039187, 32161055)
For PAVM specifically: Conduct a systematic review to determine whether HHT/PAVM patients were included in any existing Ambrisentan PAH registrational trials; assess whether PAVM+PAH co-morbidity constitutes a viable labeling sub-indication
DDI safety audit: Review all 112 documented interactions with focus on antiretroviral drugs (for PAH-HIV subgroup, given potential CYP3A4/P-gp interplay) and immunosuppressants (for PAH-CTD subgroup)
India regulatory pathway: Assess feasibility of new drug application or importation approval for Ambrisentan in India, given zero existing registrations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.